Next Article in Journal
Acute Aortic Thrombosis in Patients Receiving Cisplatin-Based Chemotherapy
Previous Article in Journal
Monitoring Response and Resistance to Treatment in Chronic Myeloid Leukemia
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 18
Issue 2
10.3747/co.v18i2.663
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

A New Standard of Care for the Management of Peritoneal Surface Malignancy

by
F. Mohamed
1,
T. Cecil
1,
B. Moran
1 and
Paul Hendrick Sugarbaker
2,*
1
Basingstoke and North Hampshire Hospital, Basingstoke, Hampshire, UK
2
Washington Cancer Institute, 106 Irving Street NW, Suite 3900, Washington, DC 20010, USA
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2011, 18(2), 84-96; https://doi.org/10.3747/co.v18i2.663
Submission received: 4 March 2011 / Revised: 8 March 2011 / Accepted: 10 March 2011 / Published: 1 April 2011

Abstract

Cancer dissemination to peritoneal surfaces was, in the past, a lethal condition with a limited survival. Clinical and pharmacologic research have shown that options for both treatment and prevention are now reality. The diseases most commonly treated include peritoneal dissemination from appendiceal malignancy, colorectal malignancy, and peritoneal mesothelioma. Selection factors are important to minimize the number of treated patients who will experience short-term benefit. Treatments involve cytoreductive surgery and perioperative chemotherapy. The intraperitoneal chemotherapy in the operating room is used with heat. Although this combined approach has been criticized, the informed oncologist will seek to identify those patients that may benefit from this more optimistic concept of peritoneal dissemination of cancer.
Keywords: Cytoreductive surgery; hyperthermic intraperitoneal chemotherapy; HIPEC; carcinomatosis; peritoneal mesothelioma; appendiceal cancer; pseudomyxoma peritonei; colorectal cancer; mitomycin C Cytoreductive surgery; hyperthermic intraperitoneal chemotherapy; HIPEC; carcinomatosis; peritoneal mesothelioma; appendiceal cancer; pseudomyxoma peritonei; colorectal cancer; mitomycin C

Share and Cite

MDPI and ACS Style

Mohamed, F.; Cecil, T.; Moran, B.; Sugarbaker, P.H. A New Standard of Care for the Management of Peritoneal Surface Malignancy. Curr. Oncol. 2011, 18, 84-96. https://doi.org/10.3747/co.v18i2.663

AMA Style

Mohamed F, Cecil T, Moran B, Sugarbaker PH. A New Standard of Care for the Management of Peritoneal Surface Malignancy. Current Oncology. 2011; 18(2):84-96. https://doi.org/10.3747/co.v18i2.663

Chicago/Turabian Style

Mohamed, F., T. Cecil, B. Moran, and Paul Hendrick Sugarbaker. 2011. "A New Standard of Care for the Management of Peritoneal Surface Malignancy" Current Oncology 18, no. 2: 84-96. https://doi.org/10.3747/co.v18i2.663

APA Style

Mohamed, F., Cecil, T., Moran, B., & Sugarbaker, P. H. (2011). A New Standard of Care for the Management of Peritoneal Surface Malignancy. Current Oncology, 18(2), 84-96. https://doi.org/10.3747/co.v18i2.663

Article Metrics

Back to TopTop